智飞生物：带状疱疹mRNA疫苗获临床试验批准

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary, Zhifei Longkema, has received approval from the National Medical Products Administration for clinical trials of an mRNA vaccine aimed at preventing shingles, which enhances the company's product portfolio and market position [2] Group 1 - Zhifei Biological's mRNA vaccine for shingles has been granted clinical trial approval [2] - The vaccine is developed using the company's proprietary mRNA technology, demonstrating good immunogenicity and safety [2] - This approval will enrich the company's adult vaccine offerings and strengthen its market position [2]